Semaglutide

Scientific Overview

Semaglutide is a long-acting GLP-1 receptor agonist and one of the most widely published incretin-receptor research compounds.

Mechanism focus

Binds the GLP-1 receptor. Research examines incretin receptor signaling and how its lipidated structure extends half-life.

Research Use Cases

• Type 2 diabetes metabolic pathway research
• Incretin receptor signaling models
• Cardiovascular outcome biology (STEP/SELECT/SUSTAIN programs)
• Incretin receptor pharmacology comparisons

Use-Case Study Notations

• Case-study notation: semaglutide has an extensive published clinical literature; see the primary publications for endpoints and methods.
• Research materials should be handled as RUO and not represented as dispensed drug product.

Selected Studies

1. 01 Once-Weekly Semaglutide in Adults with Overweight or ObesityPubMed 33567185
2. 02 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss MaintenancePubMed 33755728
3. 03 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialPubMed 36216945
4. 04 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesPubMed 27633186
5. 05 Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesPubMed 37952131

Related compounds

Tirzepatide · Retatrutide · AOD-9604